Q1 FY2018 (April 1 to June 30, 2018) Conference Call

from the beginning

Q1 FY2018 (April 1 to June 30, 2018) Conference Call

• Disclaimer Regarding Forward-looking Statements

Financial Results for Q1 FY2018

• Financial Results for Q1 FY2018 (Core Basis)

• Revenue of Major Products in Japan

• Revenue of Major Products in North America & China

• Segment Information (Core Basis)

• Financial Results for Q1 FY2018 (Full Basis)

Financial Forecasts for FY2018

• Financial Forecasts for FY2018 (Core Basis)

Research and Development

• Development Pipeline (as of July 2018)

• Clinical Development Status (Major Changes since May 11, 2018)

• Dasotraline: BED Phase 3 Study Results (SEP360-321 study)

• Alvocidib: Phase 2 Study Design & NDA Submission Target for AML

• Activities in FY2018: Clinical Development Status

Appendices

• Adjustments to Core Operating Profit

• Product Launch Target (as of July 2018)

• Regenerative Medicine/Cell Therapy Business Plan (as of July 2018)

• Psychiatry & Neurology: Apomorphine (Phase 3 study)

• Oncology: Alvocidib (r/r AML Zella 201 study)

• Oncology: Napabucasin (Pancreatic cancer 118 study)

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7